Prognostic value of immunophenotyping and gene mutations in elderly patients with acute myeloid leukemia with normal karyotype

Human Pathology

Volumn 44, Issue 1, 2013, Pages 55-61

  Dang, Harry ^a,b   Jiang, Allan ^a,b   Kamel Reid, Suzanne ^a,b   Brandwein, Joseph ^a   Chang, Hong ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Acute myeloid leukemia; Flow cytometry; Genetic mutations; Prognosis

Indexed keywords

CD135 ANTIGEN; CD15 ANTIGEN; CD34 ANTIGEN; CD56 ANTIGEN; CD7 ANTIGEN; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; MITOXANTRONE; NUCLEOPHOSMIN;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; ARTICLE; CANCER PROGNOSIS; CONTINUOUS INFUSION; EVENT FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; GENE MUTATION; HUMAN; IMMUNOPHENOTYPING; KARYOTYPE; KARYOTYPING; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY;

AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; GENETIC MARKERS; HUMANS; IMMUNOPHENOTYPING; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; RISK FACTORS; TUMOR CELLS, CULTURED;

EID: 84870684352     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2012.04.008     Document Type: Article

References (35)

1. K. Mrozek, and C.D. Bloomfield Chromosome aberrations, gene mutations and expression changes, and prognosis in adult acute myeloid leukemia Hematol Am Soc Hematol Educ Program 2006 169 177
2. C.D. Baldus, K. Mrozek, G. Marcucci, and C.D. Bloomfield Clinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations: a concise review Br J Haematol 137 2007 387 400
3. K. Mrozek, G. Marcucci, P. Paschka, S.P. Whitman, and C.D. Bloomfield Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood 109 2007 431 448
4. V. Gaidzik, and K. Dohner Prognostic implications of gene mutations in acute myeloid leukemia with normal cytogenetics Semin Oncol 35 2008 346 355
5. B. Falini, C. Mecucci, and E. Tiacci Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype N Engl J Med 352 2005 254 266
6. R.F. Schlenk, K. Dohner, and J. Krauter Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia N Engl J Med 358 2008 1909 1918
7. R.E. Gale, C. Green, and C. Allen The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia Blood 111 2008 2776 2784
8. H. Becker, G. Marcucci, and M.D. Radmacher Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B Study J Clin Oncol 28 2011 596 604
9. S.P. Whitman, K. Maharry, and M.D. Radmacher FLT3 internal tandem duplication associates with adverse outcome and gene and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study Blood 116 2010 3622 3626
10. F. Ferrara, C. Criscuolo, and C. Riccardi FLT3 mutations have no prognostic impact in elderly patients with acute myeloid leukemia and normal karyotype Am J Hematol 84 2009 532 535
11. A. Andersson, B. Johansson, C. Lassen, F. Mitelman, R. Billström, and T. Fioretos Clinical impact of internal tandem duplications and activating point mutations in FLT3 in acute myeloid leukemia in elderly patients Eur J Haematol 72 2004 307 313
12. D.L. Stirewalt, K.J. Kopecky, and S. Meshinchi FLT3 RAS, and TP53 mutations in elderly patients with acute myeloid leukemia Blood 97 2001 3589 3595
13. H. Chang, F. Salma, Q.L. Yi, B. Patterson, B. Brien, and M.D. Minden Prognostic relevance of immunophenotyping in 379 patients with acute myeloid leukemia Leuk Res 28 2004 43 48
14. D. Raspadori, D. Damiani, and M. Lenoci CD56 antigenic expression in acute myeloid leukemia identifies patients with poor clinical prognosis Leukemia 15 2001 1161 1164
15. C. Plesa, Y. Chelghoum, and A. Plesa Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia. A single-institution experience Cancer 112 2008 572 580
16. H. Chang, J. Yeung, J. Brandwein, and Q.L. Yi CD7 expression predicts poor disease free survival and post-remission survival in patients with acute myeloid leukemia and normal karyotype Leuk Res 31 2007 157 162
17. N.I. Noguera, E. Ammatuna, and D. Zangrilli Simultaneous detection of NPM1 and FLT3-ITD mutations by capillary electrophoresis in acute myeloid leukemia Leukemia 19 2005 1479 1482
18. C. Thiede, S. Koch, and E. Creutzig Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML) Blood 107 2006 4011 4020
19. J. Luo, C. Qi, W. Xu, S. Kamel-Reid, J. Brandwein, and H. Chang Cytoplasmic expression of nucleophosmin accurately predicts mutation in the nucleophosmin gene in patients with acute myeloid leukemia and normal karyotype Am J Clin Pathol 133 2010 34 40
20. F. Schneider, E. Hoster, and M. Unterhalt NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS) Blood 133 2009 5250 5253
21. V. Bardet, L.D. Costa, and C. Elie Nucleophosmin status may influence the therapeutic decision in de novo acute myeloid leukemia with normal karyotype Leukemia 20 2006 1644 1646
22. G. Marcucci, K. Maharry, and Y.Z. Wu IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study J Clin Oncol 28 2010 2348 2355
23. P. Paschka, G. Marcucci, and A.S. Ruppert Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study J Clin Oncol 26 2008 4595 4602
24. T. Büchner, WEd Berdel, and C. Haferlach Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German acute myeloid leukemia cooperative group J Clin Oncol 27 2009 61 69
25. B. Falini, P. Sportoletti, and M.P. Martelli Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives Curr Opin Oncol 21 2009 573 581
26. L. Suarez, M.B. Vidriales, and M.J. Moreno Differences in anti-apoptotic and multidrug resistance phenotypes in elderly and young acute myeloid leukemia patients are related to the maturation of blast cells Haematologica 90 2005 54 59
27. M. Schaich, R. Koch, S. Soucek, R. Repp, G. Ehninger, and T. Illmer A sensitive model for prediction of relapse in adult acute myeloid leukaemia with t(8;21) using white blood cell count, CD56 and MDR1 gene expression at diagnosis Br J Haematol 125 2004 477 479
28. Y. Kanda, T. Hamaki, and R. Yamamoto The clinical significance of CD34 expression in response to therapy of patients with acute myeloid leukemia: an overview of 2483 patients from 22 studies Cancer 88 2000 2529 2533
29. C. Röllig, C. Thiede, and M. Gramatzki A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial Blood 116 2010 971 978
30. A. Jiang, H. Jiang, J. Brandwein, S. Kamel-Reid, and H. Chang Prognostic factors in normal karyotype acute myeloid leukemia in the absence of the FLT3-ITD mutation Leuk Res 35 2011 492 498
31. H. Chang, J. Brandwein, Q.L. Yi, K. Chun, B. Patterson, and B. Brien Extramedullary infiltrates of AML are associated with CD56 expression, 11q23 abnormalities and inferior clinical outcome Leuk Res 28 2004 1007 1011
32. M.R. Baer, C.C. Stewart, and D. Lawrence Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22) Blood 90 1997 1643 1648
33. D. Raspadori, D. Damiani, and M. Michieli CD56 and PGP expression in acute myeloid leukemia: impact on clinical outcome Haematologica 87 2002 1135 1160
34. C.L. Green, K.K. Koo, R.K. Hills, A.K. Burnett, D.C. Linch, and R.E. Gale Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations J Clin Oncol 28 2010 2739 2747
35. C. Langer, G. Marcucci, and K.B. Holland Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study J Clin Oncol 27 2009 3198 3204